Introduction
As replication-competent agents, oncolytic viruses can selectively replicate in tumor cells and cause tumor cell lysis. In 1996, ONYX-015, the prototype of E1B-55 kDa-deleted adenovirus, became the first oncolytic adenovirus under clinical trials. 1, 2 The replication of E1B-55 kDa-deleted adenovirus is severely impeded in normal cells compared with wild-type adenovirus, probably because the E1B-55 kDa protein functions in assisting late viral mRNA export from the nucleus. 3 Tumor cells can recover E1B-55 kDa function in late viral mRNA transportation to the cytoplasm. The concept of using an oncolytic virus in tumor treatment was exemplified by the development of H101, 4 a similar E1B-55 kDa-deleted type 5 adenovirus with additional deletions in the E3 region. This H101 adenovirus was recently approved in China as the world's first oncolytic virus product for the treatment of nasopharyngeal carcinoma by intratumoral injection. 5 To date, more than 600 cancer patients have safely received intratumoral treatment with H101 during clinical trials (phase I through to phase III). 6 In H101 clinical trials, we noticed that the patients with fever after H101 intratumoral injection tended to show higher tumor regression response rates, not only in the locally injected tumor but also in the uninjected distant masses, than the treated patients without fever. 7 One of the best-characterized biological responses to fever is the induction of heat shock protein (HSP) expression. 8, 9 HSPs have the promiscuous ability to chaperone and present a broad repertoire of tumor antigens to dendritic cells, and activate both innate and adaptive antitumor immune responses [10] [11] [12] [13] [14] and have been extensively tested in clinical trials. [15] [16] [17] For example, vaccination with autologous tumor-derived HSP gp96-peptide complexes (HSPPC-96), extracted from autologous resected tumors, has been shown to stimulate tumor antigen-specific immune responses in patients with renal cell carcinoma and melanoma in clinical studies. 17, 18 HSPPC-96 was recently approved in Russia for treatment of renal cell carcinoma and is the world's first tumor vaccine. However, this type of HSP vaccines requires individual bespoke production from surgically resected tumor specimens ex vivo, and the quantity of HSPs is strictly limited by the size of the resected tumor mass.
On account of the limitations of ex vivo prepared HSP vaccines and the oncolytic activity of replication-competent adenovirus, we have developed an HSP-expressing mediated oncolytic adenovirus tumor vaccine, H103, as a personalized in vivo viroimmunotherapy strategy, by combining the versatile ability of HSPs to chaperone antigenic peptides and the oncolytic activity of adenoviruses. 19 The recombinant oncolytic type 2 adenovirus, overexpressing the HSP70 protein, designated as H103, can selectively replicate in tumor cells and overexpress the HSP70 protein after intratumoral injection. Therefore, it is expected that an HSP-tumor antigen complex pool is created and then released in vivo when the tumor cells are lysed by the oncolytic activity of H103. The HSPtumor antigenic peptides then stimulate a systemic antitumor immune response, leading to the killing of metastatic tumors. Although HSPs may have potential protective roles in cancer as molecular chaperones toward proteins damaged by extreme environmental stress, 20 as capacitors of phenotypic mutations due to the cancer cell's genetic instability 21 or as multiple pathway transductors in self-sufficient survival signaling, 22 HSPs may also play assistant functions to oncolytic virus by greatly enhancing oncolytic virus's efficacy on the other hand. 23 In the competition between cancer cells and oncolytic viruses, we prefer the assumption that HSPs may be more helpful to oncolytic virus compared with cancer cells, because HSP-armed oncolytic adenovirus experienced more cytotoxicity to tumor cells than the oncolytic virus without HSP gene in our earlier study. 19 In addition, given the transient expression of transgenes delivered by adenovirus, which seldom integrates into the cell's genome, 24 HSP expression induced by H103 will be abolished after the clearance of the virus from cancer cells and may have no long-lasting effect on the survival of cancer cells.
In our earlier pre-clinical study, local intratumoral treatment with H103 in mouse tumor models induced systemic immune responses that prevented subsequent tumor rechallenge, whereas the mice treated with the control oncolytic adenovirus without the HSP70 gene (H101) were still susceptible. 19 Moreover, intratumoral injection with H103, but not H101, could induce a systemic T-cell response capable of inhibiting the growth of pre-established, untreated tumors in immunocompetent mice. However, the systemic antitumor activity of H103 was impaired in nude mice, further demonstrating the critical role of T cells in the systemic antitumor activity elicited by H103 intratumoral injection. 19 The pre-clinical toxicological studies of local H103 injection did not show acute toxicities or behavioral toxicities on mice, or long-term toxicities on Rhesus monkeys (unpublished data). In the pharmacological study with rhesus monkeys, subcutaneous injection of H103 had no effect on the cardiovascular and respiratory systems (unpublished data). These pre-clinical data formed the basis for testing the antitumor activity of H103 through intratumoral administration in cancer patients. Here, we report the results of a phase I dose-escalation study of intratumoral injection of H103 in 27 patients with advanced solid tumors.
Results

Baseline and treatment characteristics
A total of 27 patients with advanced solid tumor entered into the H103 trial from a single center, the Cancer Hospital, Chinese Academy of Medical Sciences, Peking, China. All of the 27 patients were evaluated for toxicity and efficacy, and their baseline characteristics are shown in Table 1 . The dose-escalation scheme of this phase I trial is outlined in Figure 1 . Of the 27 patients, 18 received a single injection of H103 on day 1 with dose escalation from 2.5 Â 10 7 to 1.5 Â 10 12 virus particles (VPs) in a single ascending dose study (stage Ia) and nine patients received six injections of H103 on days 1, 3, 5, 8, 10 and 12 with total dose escalation from 1.5 Â 10 12 to 3.0 Â 10 12 VP in a multiple ascending dose study (stage Ib). One and two patients were recruited into cohorts 1 and 2 at the first and second dosage levels, respectively, then three patients were recruited into each cohort at a higher dosage. Dose-limiting toxicities (DLTs) were observed in the cohorts with total dosage of 1.5 Â 10 12 and 3.0 Â 10 12 VP, and up to six patients were recruited into either cohort. Phase I trial of HSP-expressing oncolytic adenovirus H103 J-L Li et al
Adverse events and maximum tolerated dose
A summary of the adverse events probably or possibly related to H103 that occurred during the 21-day treatment and observation period is shown in Table 2 . Thirteen of the 27 patients experienced one or more adverse events. The most frequent symptoms were fever (21/27) and local injection-site reaction (6/27). These adverse events were grade I/II, with an exception of grade III fever observed at the dose level of 1.5 Â 10 12 VP, at which three more patients were recruited with no further DLT observed. Five of 27 patients experienced hematological toxicities, including two mild (grade I/II) leucopenia, two grade II lymphopenia, one grade I hypochromia and two thrombocytopenia (one grade I and one grade IV). The grade IV DLT of thrombocytopenia occurred at the total dose of 3.0 Â 10 12 VP. Three more patients were recruited into this cohort and no further DLT was observed. A further dose escalation was not pursued because of the limitation in the virusmanufacturing capacity in addition to the observed H103 antitumor activity with two partial responses at the final dose level in the current trial. The MTD was therefore not reached in any of the cohorts.
Antitumoral activity
The objective responses are documented in Table 3 . Three patients, suffering from colon carcinoma, malignant myoepithelioma and melanoma, experienced a partial response to H103 treatment, with tumor shrinkage of more than 50% and a resulting local response rate of 11.1% (3/27). In addition, one patient's injected lesions shrunk by 25-50% and were categorized as minor response, and 18 patients maintained a stable disease (SD) status at the 4-week assessment. Although the patients in this trial received H103 as monodrug treatment without chemotherapy or radiotherapy, most of them had SD, with the clinical benefit rate (partial response+minor response+SD) standing at 48.1%.
It is interesting that a transient regression of certain masses among non-injected distant foci was noted in three patients. Patient 016, a 30-year-old female with malignant melanoma, received a single H103 injection into the mass in the right axilla, resulting in an SD response in the injected tumor and shrinkage of a metastasis mass in the left lung, which measured 0.8 and 0.4 cm in diameter by her pre-treatment and posttreatment computed tomography scans, respectively. Patient 019, also suffering from malignant melanoma, was treated by a single injection of H103 into the tumor lesion on the left shoulder with an SD response at posttreatment assessment, whereas a non-injected mass with a diameter of 0.5 cm in the right axilla disappeared after the treatment. Patient 023 was a 29-year-old male with malignant myoepithelioma on the neck, the forehead and in the right axilla. Six intratumoral injections of H103 into the neck mass were administered and a partial response was observed with a regression of the injected lesion from 3.0 Â 3.0 cm 2 pre-treatment to 1.0 Â 0.5 cm 2 posttreatment. In addition, a significant shrinkage of the distant mass on the forehead and SD of the right axilla mass were also noted. Although no clear-cut evidence of response is available in these three patients, due to the immeasurability of all of the cited lesions according to the Response Evaluation Criteria in Solid Tumors Figure 1 H103 dose-escalation scheme. Patients were enrolled sequentially to treatment cohorts with increasing dose according to the modified continual reassessment method.
Phase I trial of HSP-expressing oncolytic adenovirus H103 J-L Li et al criteria, 25 this antitumor effect of distant lesions will be confirmed in further studies.
Neutralizing antibody response to intratumoral H103
Neutralizing antibody titers to H103 were positive in 26 of 27 cases (96.3%) at baseline (Table 1) , ranging from 5:1 to 640:1, with a median titer of 40:1. Titers increased in almost all the patients following a single injection with H103, regardless of the viral dose. The median antibody titer after a single injection in the single ascending dose study was 1:1280 on day 14 post-treatment, compared with 1:80 at the baseline. The antibody titer was gradually elevated within 2 weeks post-treatment, with a tendency to plateau at 2-3 weeks (Figure 2a) . No clear correlation was demonstrated between neutralizing antibody titers and viral dose, antitumor activity or toxicity. The pre-existing neutralizing antibody titer was not found to have impact on H103 efficacy. 
Levels of leukocytes and leukocyte subsets
Discussion
According to the current literature, this is the first reported clinical trial of an HSP-expressing replicationselective virus. The intratumoral injection of HSPexpressing oncolytic virus H103 was well tolerated at doses up to 3.0 Â 10 12 VP and the maximum tolerated dose (MTD) was not reached at the highest tested dose. The adverse events were mild-to-moderate injection-site reaction, fever, hematological toxicities with exceptions Phase I trial of HSP-expressing oncolytic adenovirus H103 J-L Li et al of one grade III fever at 1.5 Â 10 12 VP and one grade IV thrombocytopenia at 3.0 Â 10 12 VP. Fever was the most common adverse event, most of which were mild, responded well to antipyretic drugs and recovered spontaneously within 24 h post-treatment of H103. The fever may not necessarily be a bad effect of the oncolytic virus treatment. In our earlier H101 clinical trials, patients with fever after H101 treatment tended to show higher tumor regression in both H101-injected tumor and distant metastases. 7 The therapeutic index of oncolytic adenovirus could also be increased by fever and the concomitant induction of a heat shock response could significantly improve ONYX-015 cancer therapy. 26, 27 In the current trial of H103, an association between fever and clinical benefit was not found.
Mild-to-moderate hematological toxicities have generally been observed in the trials of adenoviruses using the virus as a gene therapy vector or oncolytic virus. [28] [29] [30] [31] Five of our 27 patients experienced hematological toxicities including one case of grade IV thrombocytopenia at the total dose of 3.0 Â 10 12 VP, a patient whose baseline platelet count was 200 Â 10 9 per l, whereas the mean platelet volume (MPV) was 6.8 fl, much lower than the normal range (9.4-12.5 fl). Although the mean platelet volume measurements can be quite variable, 32 low mean platelet volume implies that inhibition of platelet production occurred before the H103 treatment. This patient recovered after platelet transfusion within 3 months after H103 treatment.
Owing to the lytic nature of the oncolytic virus H103, a local regression of injected lesions was expected and did occur in three patients with partial responses and in one patient with minor response. An earlier in vivo animal study has clearly demonstrated the systemic efficacy of H103, and the hypothesis of an immune stream comprising HSP-tumor antigen complex release, antigen presentation by dendritic cell, lymphocyte activation and metastatic tumor cell killing was supposed as the H103 mechanism. 19 However, no definite antitumor efficacy on non-injected metastasis masses was definitely demonstrated in this study according to the RESCIST tumor response criteria. However, transient regressions of certain distant non-injected tumor lesions were noted in three patients and most of the patients in this trial had SD response for non-injected tumors, despite receiving monodrug H103 treatment without chemotherapy or radiotherapy. In addition, this phase I study was designed to evaluate the safety of H103 and the treatment was not administered as a tumor vaccine that would normally involve immunization several times. 33 Thus, further studies on the potential distant antitumor activity of H103 are warranted in a phase II trial, in which H103 should be administered according to the tumor vaccine schedule comprising prime, boost and maintenance immunizations to initiate and strengthen the systemic antitumor immune response induced by H103.
The immune response, particularly the T-cell response induced by a tumor vaccine, is the key to tumor immunotherapy. As described in our earlier study, the H103-induced personalized in vivo immune response was mainly intermediated by T cells, particularly CD8 T cells. 19 However, well-defined tumor antigens are prerequisites for the specific assessment of the T-cell response, because the tumor antigens are different even among the same kind of tumors. 34 Owing to the tumor heterogeneity of our recruited patients, specific cellular immune response could not be easily assessed in this study. + T cells were seemingly increased ( Figure  2b) although not statistically significant. In the further phase II trial, cellular immunity will be assessed by ELISPOT and Tetramer methods in certain patients with a defined tumor. 35, 36 In conclusion, H103 is well tolerated and can be safely administered by intratumoral injection and displays oncolytic activity at a total dose of 3.0 Â 10 12 VP as evidenced by local partial response responses. The results of this study suggest a potential role for this in vivo personalized vaccination strategy against tumors. On the basis of the data of safety and encouraging antitumor activity, the patients with malignant melanoma and non-small cell lung cancer are currently undergoing H103 phase II trials.
Patients and methods
Patient selection
Eligibility requirements included histologically confirmed solid malignant tumors that were recurrent and refractory to radiotherapy and/or chemotherapy with no or poor further treatment options. The tumor had to be amenable and safe for direct injection and measurement, either clinically or radiographically. All patients were at the age of 18-70 years, with a Karnofsky performance status of X60% and a life expectancy of 3 months. Inclusion in the study required the patient to sign and date the informed consent form. The main exclusion criteria included hypersensitivity to H103-like products, use of an immune inhibitor within 30 days, pregnant or nursing, ongoing uncontrolled active infection, symptomatic nervous system metastasis or primary tumor, concomitant other malignant tumors and receiving antiviral drug treatment.
Manufacture of H103 adenovirus
H103, a recombinant human group C type 2 adenovirus, 19 does not express the E1B-55 kDa peptide, thus resembling the E1B-55 kDa-deleted ONYX-015 virus, and harbors an HSP70 expression cassette under the CMV-IE promoter in the E1 region. H103 was manufactured using the HEK293 cell line, obtained from Shanghai Sunway Biotech Co. Ltd, Shanghai, PR China as a cell matrix according to Chinese GMP with an infectious virus ratio of 1:60 (TCID 50 /viral particles). The virus was supplied frozen (À20 1C) in a single-use vial with 2.5 Â 10 11 VP. Before use, vials were thawed at room temperature and diluted with normal saline to the appropriate titer for dosing.
Study design and dose-escalation scheme
The IND application for intratumoral injection of H103 was approved by the State Food and Drug Administration of China and this protocol was approved by the ethics committee of the Cancer Hospital of Chinese Academy of Medical Sciences in Beijing. This was a single-center phase I dose-escalation study. DLT was Phase I trial of HSP-expressing oncolytic adenovirus H103 J-L Li et al defined as according to the National Cancer Institute of Canada common toxicity criteria (version 3.0) grade III and IV toxicity attributed to H103 administration. Patients were enrolled sequentially into treatment cohorts of increasing dose, according to a modified continual reassessment method. 37 If a DLT related to H103 was observed in a cohort, up to six patients were to be enrolled at that dose level until one or more of the additional patients exhibited a DLT. After that, the MTD was defined and no further escalation took place. If six patients were enrolled at that dose level without an additional DLT, enrollment could be continued to the next cohort receiving a higher dose. The MTD was defined as the dose immediately below the dose at which two of the six patients experienced a DLT after treatment with H103. The current trial contained a single doseascending study (stage Ia) and a multiple dose-ascending study (stage Ib). Patients in stage Ia received a single injection of H103 on day 1 with dosage from 2.5 Â 10 7 to 1.5 Â 10 12 VP. As the tumor cytolysis of oncolytic virus can be strengthened by repeated viral infection and the durable antigen release contributes to the immunity activation, the total dosage was divided by six injections within 2 weeks in stage Ib study and the patients received H103 injection on days 1, 3, 5, 8, 10 and 12 with a total dosage from 1.5 Â 10 12 VP. H103 was diluted with normal saline to about 30% tumor volume to be injected.
Evaluation of toxicity and response
The main end point of the study was safety. Patients were evaluated for toxicity over a 21-day observation period if they received at least one dose of H103. The definition of adverse-event severity was categorized and graded according to the National Cancer Institute of Canada common toxicity criteria (version 3.0). Response to therapy was assessed by clinical or radiological (computed tomography or magnetic resonance imaging) tumor measurement at week 4 post-treatment. According to WHO solid tumor response evaluation criteria, 38 complete response was defined as the complete disappearance of all tumors at the assessed site, partial response as regression of the tumor mass by X50% but o100%, minor response as regression of the tumor mass by 425% but o50%, SD as tumor decrease or increase in size byp25% and progressive disease as 425% increase in overall tumor cross-sectional area.
Leukocytes and leukocyte subset monitoring
The H103 effect on the immune system was measured by lymphocyte analysis using baseline and day-21 post-treatment blood samples. The peripheral blood mononuclear cells were stained with anti-CD3, anti-CD4, anti-CD8, anti-CD28, anti-CD56 and anti-CD16 antibodies. The lymphocyte subsets were then assayed by fluorescence-activated cell sorting.
Anti-Ad-neutralizing antibody titer assessment H103-neutralizing antibodies were assessed at baseline, and at days 3, 7, 14 and 21 post-treatment. The patients' plasma and control samples were incubated at 55 1C for 30 min to inactivate complement, followed by serial dilution with 1640 growth medium from 1:10 to 1:1280. Each dilution was mixed with H103 stock at a titer prequalified to produce 15-20 plaques per well in 1640 growth medium within a 96-well plate. The patients' samples and controls were incubated for 1 h at room temperature and applied to HEK293 cells in 96-well plates. After 14 days of incubation at 37 1C, in 5% CO 2 , plates were read by counting the number of plaqueforming units per well. The titer of neutralizing antibody for each sample was reported as the dilution of plasma that achieved a 50% reduction in the number of plaques compared with the virus control without antibody.
